EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Quality considerations and major pitfalls for high throughput DNA-based newborn screening for severe combined immunodeficiency and spinal muscular atrophy

Jessica Bzdok iD, Ludwig Czibere iD, Siegfried Burggraf iD, Olfert Landt, Esther M Maier, Wulf Röschinger, Michael H Albert, Sebastian Hegert iD, Nils Janzen iD, Marc Becker, Jürgen Durner

PLOS ONE · 28.06.2024 · 19 (6) · e0306329

DOI: 10.1371/journal.pone.0306329 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 28.06.2024. Verfasst von Jessica Bzdok und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Operative/Restorative Dentistry, Periodontology and Pedodontics, Ludwig-Maximilians-Universität München, Munich, Germany. Hauptthemen laut MEDLINE: Neonatal Screening, Muscular Atrophy, Spinal, Severe Combined Immunodeficiency, DNA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Many newborn screening programs worldwide have introduced screening for diseases using DNA extracted from dried blood spots (DBS). In Germany, DNA-based assays are currently used to screen for severe combined immunodeficiency (SCID), spinal muscular atrophy (SMA), and sickle cell disease (SCD).

Methods

This study analysed the impact of pre-analytic DNA carry-over in sample preparation on the outcome of DNA-based newborn screening for SCID and SMA and compared the efficacy of rapid extraction versus automated protocols. Additionally, the distribution of T cell receptor excision circles (TREC) on DBS cards, commonly used for routine newborn screening, was determined.

Results

Contaminations from the punching procedure were detected in the SCID and SMA assays in all experimental setups tested. However, a careful evaluation of a cut-off allowed for a clear separation of true positive polymerase chain reaction (PCR) amplifications. Our rapid in-house extraction protocol produced similar amounts compared to automated commercial systems. Therefore, it can be used for reliable DNA-based screening. Additionally, the amount of extracted DNA significantly differs depending on the location of punching within a DBS.

Conclusions

Newborn screening for SMA and SCID can be performed reliably. It is crucial to ensure that affected newborns are not overlooked. Therefore a carefully consideration of potential contaminating factors and the definition of appropriate cut-offs to minimise the risk of false results are of special concern. It is also important to note that the location of punching plays a pivotal role, and therefore an exact quantification of TREC numbers per μl may not be reliable and should therefore be avoided.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neonatal ScreeningMuscular Atrophy, SpinalSevere Combined ImmunodeficiencyDNAHumansInfant, NewbornDried Blood Spot TestingHigh-Throughput Screening AssaysPolymerase Chain Reaction

Substanzen

DNA

Autor:innen und Institutionen

  • Department of Operative/Restorative Dentistry, Periodontology and Pedodontics, Ludwig-Maximilians-Universität München, Munich, Germany.
  • Laboratory Becker MVZ GbR, Munich, Germany.
  • TIB Molbiol Syntheselabor GmbH, Berlin, Germany.
  • Department of Paediatrics, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
  • Screening-Labor Hannover, Hanover, Germany.
  • Department of Clinical Chemistry, Hanover Medical School, Hanover, Germany.

ORCID-Profile: Jessica Bzdok, Ludwig Czibere, Siegfried Burggraf, Sebastian Hegert, Nils Janzen

Zitieren

APA

Bzdok, J., Czibere, L., Burggraf, S., Landt, O., Maier, E. M., Röschinger, W., Albert, M. H., Hegert, S., Janzen, N., Becker, M., & Durner, J. (2024). Quality considerations and major pitfalls for high throughput DNA-based newborn screening for severe combined immunodeficiency and spinal muscular atrophy. PLOS ONE, 19(6), e0306329. https://doi.org/10.1371/journal.pone.0306329

Vancouver

Bzdok J, Czibere L, Burggraf S, Landt O, Maier EM, Röschinger W, et al. Quality considerations and major pitfalls for high throughput DNA-based newborn screening for severe combined immunodeficiency and spinal muscular atrophy. PLOS ONE. 2024;19(6):e0306329. doi:10.1371/journal.pone.0306329

BibTeX
@article{Bzdok2024,
  author = {Bzdok, Jessica and Czibere, Ludwig and Burggraf, Siegfried and Landt, Olfert and Maier, Esther M and Röschinger, Wulf and Albert, Michael H and Hegert, Sebastian and Janzen, Nils and Becker, Marc and Durner, Jürgen},
  title = {Quality considerations and major pitfalls for high throughput DNA-based newborn screening for severe combined immunodeficiency and spinal muscular atrophy},
  journal = {PLOS ONE},
  year = {2024},
  volume = {19},
  number = {6},
  pages = {e0306329},
  doi = {10.1371/journal.pone.0306329}
}
Kostenlos starten →